HRP20131229T1 - Lijeäśenje ateroskleroze - Google Patents
Lijeäśenje ateroskleroze Download PDFInfo
- Publication number
- HRP20131229T1 HRP20131229T1 HRP20131229AT HRP20131229T HRP20131229T1 HR P20131229 T1 HRP20131229 T1 HR P20131229T1 HR P20131229A T HRP20131229A T HR P20131229AT HR P20131229 T HRP20131229 T HR P20131229T HR P20131229 T1 HRP20131229 T1 HR P20131229T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- peptide
- use according
- atherosclerosis
- fgfpahvfidwlqsln
- Prior art date
Links
- 201000001320 Atherosclerosis Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 7
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Marine Sciences & Fisheries (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (7)
1. Spoj, naznačen time, da obuhvaća amino kiselinsku sekvencu FGFPAHVFIDWLQSLS ili FGFPAHVYIDWLQSLS ili FGFPAHVFIDWLQSLN za uporabu u prevenciji i/ili liječenju ateroskleroze, periferne arterijske okluzijske bolesti, koronarne srčane bolesti ili apoplektičkog cerebralnog napada.
2. Spoj za uporabu prema zahtjevu 1, naznačen time, da je taj spoj povezan na farmaceutski prihvatljiv nosač, posebno na KLH (Keyhole Limpet Hemocyanin).
3. Spoj za uporabu prema bilo kojem zahtjevu 1 do 2, naznačen time, da je taj spoj formuliran za intradermalnu, supkutanu ili intramuskularnu primjenu.
4. Spoj za uporabu prema bilo kojem zahtjevu 1 do 3, naznačen time, da je taj spoj formuliran s pomoćnim sredstvom, posebno s aluminijskim hidroksidom.
5. Peptid, naznačen time, da se sastoji od barem jedne amino kiselinske sekvence odabrane iz skupine koju čine: FGFPAHVFIDWLQSLS ili FGFPAHVYIDWLQSLS i FGFPAHVFIDWLQSLN.
6. Farmaceutska formulacija, naznačena time, da obuhvaća barem jedan peptid prema zahtjevu 5.
7. Formulacija prema zahtjevu 6, naznačena time, da je peptid povezan na farmaceutski prihvatljiv nosač, posebno na KLH (Keyhole Limpet Hemocyanin).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0125807A AT505574B1 (de) | 2007-08-10 | 2007-08-10 | Mimotope zur behandlung von atherosklerose |
PCT/AT2008/000281 WO2009021254A1 (en) | 2007-08-10 | 2008-08-08 | Treatment of atherosclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20131229T1 true HRP20131229T1 (hr) | 2014-01-31 |
Family
ID=39865273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20131229AT HRP20131229T1 (hr) | 2007-08-10 | 2013-12-27 | Lijeäśenje ateroskleroze |
Country Status (18)
Country | Link |
---|---|
US (2) | US8618046B2 (hr) |
EP (1) | EP2190451B1 (hr) |
JP (2) | JP2010535818A (hr) |
KR (1) | KR20100080507A (hr) |
CN (1) | CN101835483B (hr) |
AT (1) | AT505574B1 (hr) |
AU (1) | AU2008286667B2 (hr) |
CA (1) | CA2695988A1 (hr) |
CY (1) | CY1114760T1 (hr) |
DK (1) | DK2190451T3 (hr) |
ES (1) | ES2439703T3 (hr) |
HK (1) | HK1145634A1 (hr) |
HR (1) | HRP20131229T1 (hr) |
PL (1) | PL2190451T3 (hr) |
PT (1) | PT2190451E (hr) |
SI (1) | SI2190451T1 (hr) |
TW (1) | TWI442933B (hr) |
WO (1) | WO2009021254A1 (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT506535B1 (de) * | 2008-02-22 | 2010-04-15 | Affiris Forschungs & Entwicklungs Gmbh | Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden |
EP2532359A1 (en) | 2011-06-10 | 2012-12-12 | Affiris AG | CETP fragments |
CA3120508A1 (en) | 2013-10-28 | 2015-05-07 | Dots Technology Corp. | Allergen detection |
CN105596811A (zh) * | 2015-11-10 | 2016-05-25 | 王冬梅 | 主治动脉粥样硬化的中药组合物及制法 |
CN110167583A (zh) * | 2016-12-15 | 2019-08-23 | 泰伦基国际有限公司 | 一种治疗冠状动脉粥样硬化及其并发症的方法 |
EP3658581A1 (en) | 2017-07-24 | 2020-06-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies and peptides to treat hcmv related diseases |
CN117244043A (zh) * | 2023-11-02 | 2023-12-19 | 徐州医科大学附属医院 | 破伤风类毒素在治疗血管内皮细胞损伤中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410022B1 (en) | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
AT500835B1 (de) * | 2004-09-13 | 2007-12-15 | Affiris Forschungs & Entwicklungs Gmbh | Cholinestertransport-protein-mimotop als atherosklerose-medikament |
US20060276400A1 (en) | 2005-06-06 | 2006-12-07 | Hedy Adari | Modulation of cholesteryl ester transfer protein (CETP) activity |
CN101384621A (zh) * | 2005-11-10 | 2009-03-11 | 受体生物公司 | 产生受体和配体同种型的方法 |
-
2007
- 2007-08-10 AT AT0125807A patent/AT505574B1/de not_active IP Right Cessation
-
2008
- 2008-08-08 CA CA2695988A patent/CA2695988A1/en not_active Abandoned
- 2008-08-08 JP JP2010520379A patent/JP2010535818A/ja active Pending
- 2008-08-08 US US12/673,081 patent/US8618046B2/en not_active Expired - Fee Related
- 2008-08-08 PT PT87828091T patent/PT2190451E/pt unknown
- 2008-08-08 DK DK08782809.1T patent/DK2190451T3/da active
- 2008-08-08 KR KR1020107005287A patent/KR20100080507A/ko not_active Application Discontinuation
- 2008-08-08 EP EP08782809.1A patent/EP2190451B1/en not_active Not-in-force
- 2008-08-08 WO PCT/AT2008/000281 patent/WO2009021254A1/en active Application Filing
- 2008-08-08 TW TW097130215A patent/TWI442933B/zh active
- 2008-08-08 ES ES08782809.1T patent/ES2439703T3/es active Active
- 2008-08-08 AU AU2008286667A patent/AU2008286667B2/en not_active Ceased
- 2008-08-08 SI SI200831094T patent/SI2190451T1/sl unknown
- 2008-08-08 CN CN2008801113067A patent/CN101835483B/zh not_active Expired - Fee Related
- 2008-08-08 PL PL08782809T patent/PL2190451T3/pl unknown
-
2010
- 2010-12-23 HK HK10112056.4A patent/HK1145634A1/xx not_active IP Right Cessation
-
2013
- 2013-09-25 JP JP2013198877A patent/JP2014040438A/ja active Pending
- 2013-11-21 US US14/086,159 patent/US20140179900A1/en not_active Abandoned
- 2013-12-27 HR HRP20131229AT patent/HRP20131229T1/hr unknown
-
2014
- 2014-01-16 CY CY20141100039T patent/CY1114760T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CN101835483B (zh) | 2012-09-26 |
EP2190451A1 (en) | 2010-06-02 |
DK2190451T3 (da) | 2013-11-04 |
HK1145634A1 (en) | 2011-04-29 |
CN101835483A (zh) | 2010-09-15 |
WO2009021254A1 (en) | 2009-02-19 |
AU2008286667B2 (en) | 2013-04-04 |
US20110275556A1 (en) | 2011-11-10 |
PL2190451T3 (pl) | 2014-03-31 |
US8618046B2 (en) | 2013-12-31 |
CA2695988A1 (en) | 2009-02-19 |
TWI442933B (zh) | 2014-07-01 |
US20140179900A1 (en) | 2014-06-26 |
KR20100080507A (ko) | 2010-07-08 |
PT2190451E (pt) | 2013-12-23 |
JP2014040438A (ja) | 2014-03-06 |
CY1114760T1 (el) | 2016-12-14 |
TW200911282A (en) | 2009-03-16 |
ES2439703T3 (es) | 2014-01-24 |
AT505574A1 (de) | 2009-02-15 |
AT505574B1 (de) | 2009-09-15 |
EP2190451B1 (en) | 2013-10-16 |
SI2190451T1 (sl) | 2013-12-31 |
JP2010535818A (ja) | 2010-11-25 |
AU2008286667A1 (en) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20131229T1 (hr) | Lijeäśenje ateroskleroze | |
HRP20170328T1 (hr) | Cjepivo pcsk9 | |
MY174002A (en) | Combination theraphy for the treatment of diabetes | |
WO2009043451A3 (en) | Use of chorionic gonadotropin-beta (109-145) as a therapeutic agent | |
WO2009039982A3 (en) | Use of gip alone or in combination with dynorphin b as a therapeutic agent | |
WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
WO2009043450A8 (en) | Use of neurotrophic factor for retinal cholinergic neurons (nfrcn) and chorionic gonadotropin-beta (109-145) as therapeutic agents | |
WO2009043464A3 (en) | Astressin and beta- endorphin for use as therapeutic agents | |
WO2009043465A3 (en) | Use of beta-endorphin as a therapeutic agent | |
RU2013119607A (ru) | Полициклические гетероциклические соединения и способы их применения для лечения вирусных заболеваний | |
WO2009039969A3 (en) | Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent | |
WO2009040025A3 (en) | Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent | |
WO2009033770A3 (en) | Calcitonin c-terminal flanking peptide for use as a therapeutic agent | |
WO2009088838A3 (en) | Triarylmethane analogs and their use in treating cancers | |
DK1885333T3 (da) | Farmaceutisk formulering af apomorphin til bukkal indgivelse | |
AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
WO2009033738A3 (en) | Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent | |
WO2006125178A3 (en) | Tricyclic pyridazine compounds and their uses as therapeutic agents | |
WO2009040085A3 (en) | Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) | |
WO2009033722A8 (en) | Use of a octreotide as a therapeutic agent | |
BR112012022209A2 (pt) | composições farmacêuticas compreendendo monoterpenos | |
JO2820B1 (en) | Combination of refined thiazolium salt or a primary compound and artemisinin or a derivative thereof to treat serious malaria cases | |
MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
WO2009033816A3 (en) | Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent | |
WO2011151786A3 (en) | Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer |